1. Salvage Chemotherapy with R-DHAP in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma.
- Author
-
Schirmbeck NG, Mey UJ, Olivieri A, Ko YD, Kaiser U, Flieger D, Witzens-Harig M, and Schmidt-Wolf IG
- Subjects
- Adult, Aged, Antineoplastic Combined Chemotherapy Protocols adverse effects, Cisplatin adverse effects, Cisplatin therapeutic use, Cytarabine adverse effects, Cytarabine therapeutic use, Dexamethasone adverse effects, Dexamethasone therapeutic use, Female, Humans, Kaplan-Meier Estimate, Lymphoma, Non-Hodgkin diagnosis, Lymphoma, Non-Hodgkin mortality, Male, Middle Aged, Neoplasm Staging, Retreatment, Rituximab administration & dosage, Salvage Therapy, Treatment Outcome, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Drug Resistance, Neoplasm, Lymphoma, Non-Hodgkin drug therapy, Lymphoma, Non-Hodgkin pathology
- Abstract
This analysis reports on 72 patients with relapsed or refractory non-Hodgkin lymphoma who were treated with R-DHAP salvage chemotherapy regimen followed by high-dose chemotherapy and stem cell transplantation. The overall remission rate was 58.3%. Median time of follow-up was 28.7 months. Median progression-free survival was 29 months, estimated median overall survival was 37 months. Within a matched pair analysis these results were compared to a group that received DHAP salvage therapy without rituximab showing similar overall response rates and better estimated five-year overall survival of 59.2% versus 43.5%. R-DHAP therapy was shown to be effective and feasible with acceptable toxicity.
- Published
- 2016
- Full Text
- View/download PDF